ENGERIX-B

GlaxoSmithKline Inc🇨🇦 Health Canada

Approval Id: 7a115f31ca1d5d12
Drug Approval Canada Name: ENGERIX-B
Product Name: ENGERIX-B
Status: Marketed
Status Date: 2019-10-07
Original Market Date: 2019-10-07
Din: 02487020
Drug Class: Human
Dosage Form: Suspension
Route Of Administration: Intramuscular
Schedule: Schedule D
Ahfs: 80:12.00
Atc Original: J07BC01 HEPATITIS B, PURIFIED ANTIGEN
Atc Name: j 07 bc 01
Aig Number: 0119570002
Company Name: GlaxoSmithKline Inc
Company Address: 800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path: /organization/glaxosmithkline-inc

HEPATITIS B SURFACE ANTIGEN (RECOMBINANT)

10 MCG / 0.5 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

7a115f31ca1d5d12

Type

Standard